Corcept Therapeutics Incorporated
CORT
Updated: 24/09/2026, 17:08:04
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
No summaries found.
- Share price
- $113.18
- Market cap
- $12.24B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Joseph K. Belanoff
- Employees
- 730
- IPO date
- 14/04/2004
- Beta
- 0.446
- Last dividend
- $0.00
- Day range
- $111.68 – $114.16
- 52-week range
- $28.66 – $126.38
- 1-day performance
- 0.21%
- 1-year performance
- 294.91%
- Current drawdown (1Y)
- -10.44%
- CIK
- 0001088856
- CUSIP
- 218352102
- ISIN
- US2183521028
- Created
- 07/12/2025, 03:24:52
- Last update
- 24/09/2026, 17:08:04
Track Corcept Therapeutics Incorporated with an AI analyst
See which prediction-market events move CORT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
CORT Stock Rises 42% in a Month: Here's What You Should Know
Zacks Investment Research • STOCK • 08/06/2026, 15:06:11
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Business Wire • STOCK • 29/05/2026, 18:33:00
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Zacks Investment Research • STOCK • 28/05/2026, 13:16:15
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
Zacks Investment Research • STOCK • 19/05/2026, 12:55:41
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Zacks Investment Research • STOCK • 15/05/2026, 14:51:07
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Seeking Alpha • STOCK • 04/05/2026, 16:53:10
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 01/05/2026, 07:31:34
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • STOCK • 30/04/2026, 23:45:17
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
PRNewsWire • STOCK • 21/04/2026, 17:02:00
CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
GlobeNewsWire • STOCK • 21/04/2026, 14:38:00
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewsWire • STOCK • 21/04/2026, 14:00:00
CORT FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action - CORT
Newsfile Corp • STOCK • 21/04/2026, 00:30:00